Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study.
COVID-19
Cancer
outcome
treatment delay
Journal
Clinical Medicine Insights. Oncology
ISSN: 1179-5549
Titre abrégé: Clin Med Insights Oncol
Pays: United States
ID NLM: 101525771
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
03
2021
accepted:
08
08
2021
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
17
9
2021
Statut:
epublish
Résumé
Coronavirus disease (COVID-19), an acute respiratory syndrome caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has rapidly spread worldwide, significantly affecting the outcome of a highly vulnerable group such as cancer patients. The aim of the present study was to evaluate the clinical impact of COVID-19 infection on outcome and oncologic treatment of cancer patients. We retrospectively enrolled cancer patients with laboratory and/or radiologic confirmed SARS-CoV-2 infection, admitted to our center from February to April 2020. Descriptive statistics were used to summarize the clinical data and univariate analyses were performed to investigate the impact of anticancer treatment modifications due to COVID-19 outbreak on the short-term overall survival (OS). Among 61 patients enrolled, 49 (80%) were undergoing anticancer treatment and 41 (67%) had metastatic disease. Most patients were men; median age was 68 years. Median OS was 46.6 days (40% of deaths occurred within 20 days from COVID-19 diagnosis). Among 59 patients with available data on therapeutic course, 46 experienced consequences on their anticancer treatment schedule. Interruption or a starting failure of the oncologic therapy correlated with significant shorter OS. Anticancer treatment delays did not negatively affect the OS. Lymphocytopenia development after COVID was significantly associated with worst outcome. COVID-19 diagnosis in cancer patients may affect their short-term OS, especially in case of interruption/starting failure of cancer therapy. Maintaining/delaying cancer therapy seems not to influence the outcome in selected patients with recent COVID-19 diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease (COVID-19), an acute respiratory syndrome caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has rapidly spread worldwide, significantly affecting the outcome of a highly vulnerable group such as cancer patients. The aim of the present study was to evaluate the clinical impact of COVID-19 infection on outcome and oncologic treatment of cancer patients.
PATIENT AND METHODS
METHODS
We retrospectively enrolled cancer patients with laboratory and/or radiologic confirmed SARS-CoV-2 infection, admitted to our center from February to April 2020. Descriptive statistics were used to summarize the clinical data and univariate analyses were performed to investigate the impact of anticancer treatment modifications due to COVID-19 outbreak on the short-term overall survival (OS).
RESULTS
RESULTS
Among 61 patients enrolled, 49 (80%) were undergoing anticancer treatment and 41 (67%) had metastatic disease. Most patients were men; median age was 68 years. Median OS was 46.6 days (40% of deaths occurred within 20 days from COVID-19 diagnosis). Among 59 patients with available data on therapeutic course, 46 experienced consequences on their anticancer treatment schedule. Interruption or a starting failure of the oncologic therapy correlated with significant shorter OS. Anticancer treatment delays did not negatively affect the OS. Lymphocytopenia development after COVID was significantly associated with worst outcome.
CONCLUSIONS
CONCLUSIONS
COVID-19 diagnosis in cancer patients may affect their short-term OS, especially in case of interruption/starting failure of cancer therapy. Maintaining/delaying cancer therapy seems not to influence the outcome in selected patients with recent COVID-19 diagnosis.
Identifiants
pubmed: 34526833
doi: 10.1177/11795549211043427
pii: 10.1177_11795549211043427
pmc: PMC8436296
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11795549211043427Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Thorac Imaging. 2020 Jul;35(4):228-233
pubmed: 32271278
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
J Thorac Oncol. 2020 Jul;15(7):1119-1136
pubmed: 32422364
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
N Engl J Med. 2020 Aug 6;383(6):e38
pubmed: 32502334
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
J Thorac Imaging. 2020 Jul;35(4):219-227
pubmed: 32324653
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
J Immunol. 2002 Oct 15;169(8):4288-97
pubmed: 12370360
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Leukemia. 2020 Jun;34(6):1637-1645
pubmed: 32332856